Only men with prostate tumors of the luminal B subtype benefited from adding apalutamide to salvage radiation in the phase 2 ...

A UCLA study shows that a new treatment combining a radioactive drug with radiation therapy could help delay hormone therapy ...

Dr. Wallen: When the prostate cancer is only in the prostate and hasn't spread elsewhere, the standard of care treatments are ...

A Gleason reading of 9 one of the most virulent forms of prostate cancer is now fueling ex-President Joe Biden’s treatment ...

For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before ...

SBRT may ease toxicity, but the lower doses could come at the expense of cancer control, new data indicate. Experts suggest a ...

Prostate cancer is the most common cancer among men after skin cancer, with approximately 1 in 8 men diagnosed in their ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic ...

Recurrent prostate cancer patients with luminal B tumors may benefit from hormone therapy added to radiation following surgery.

A phase 2 trial tested the efficacy of local stereotactic body radiation therapy (SBRT) use after radical prostatectomy.

A genetic test could guide the use of hormone therapy for men with recurrent prostate cancer after surgery, according to data ...

The hydrogel spacer minimizes radiation exposure to the rectum, decreasing bowel, urinary, and sexual complications. Recent analysis reveals that rectal spacers significantly lower recurrence rates in ...